# Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

> **NCT06686524** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 18 (estimated)

## Conditions studied

- Dermatomyositis, Juvenile
- Dermatomyositis

## Interventions

- **DRUG:** Anti-CD19 UCAR-T cells

## Key facts

- **NCT ID:** NCT06686524
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2026-11-10
- **Final completion:** 2027-11-10
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06686524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06686524, "Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06686524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*